Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 10:05:27 09/03/2026 pm IST			5-day change	1st Jan Change
65.00 ^GBX	-3.70%		+4.84%	+12.07%

24/02	Avacta hails new data supporting proprietary preCision platform	AN
24/02	Avacta Therapeutics Plans FAP-Exd's Clinical Trials After 'Favorable' Experimental Analysis	MT

Avacta : Research & Development Spotlight Series, Episode 13

Published on 12/18/2025 at 03:34 pm IST

Publicnow

AVACTA GROUP PLC

-3.70%

In this episode of the R&D Spotlight series the team dive into FAP-Exd (AVA6103) and look under the hood of the sustained release mechnism.

Attachments

Original document
Permalink

Disclaimer

Avacta Group plc published this content on December 18, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on December 18, 2025 at 10:03 UTC.

Latest news about Avacta Group Plc

24/02	Avacta hails new data supporting proprietary preCision platform	AN
24/02	Avacta Therapeutics Plans FAP-Exd's Clinical Trials After 'Favorable' Experimental Analysis	MT
24/02	Avacta's pre\|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis	CI
09/02	Avacta appoints new chief scientific officer, plans clinical trials	AN
09/02	Avacta Therapeutics Names Chemistry Vice President as Chief Scientific Officer	MT
09/02	Avacta Therapeutics Announces Executive Changes	CI
04/02	Avacta Therapeutics Announces Two Key Clinical Updates to its Faridoxorubicin Clinical Program	CI
03/02	Avacta reports progress in faridoxorubicin clinical programme	AN
03/02	Avacta reports progress in faridoxorubicin clinical programme	AN
03/02	Avacta Group Updates Trial Protocol in Faridoxorubicin Program	MT
03/02	Avacta Therapeutics says cardiac dosing limit removed in Faridoxorubicin program	RE
21/01	Avacta Therapeutics Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug Application for the Second Pre\|Cision® Medicine, Fap-Exatecan	CI
21/01	EARNINGS AND TRADING: Kenmare meets guidance, plans to lower costs	AN
21/01	Avacta announces US FDA clearance of the investigational new drug application for the second pre\|CISION medicine, FAP-Exatecan	RE
21/01	Avacta Therapeutics Wins US FDA Nod to Start Early-stage Trial of Cancer Drug FAP-Exd	MT

Chart Avacta Group Plc

Duration

Period

AVCT: Dynamic Chart

Company Profile

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Employees

151

Sector

Biotechnology & Medical Research

More about the company